XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Statements of Operations and Comprehensive Loss - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Costs and expenses:    
Research and development expense $ 6,025,461 $ 5,418,706
General and administrative expense 5,089,566 5,522,312
Total costs and expenses 11,115,027 10,941,018
Loss from operations (11,115,027) (10,941,018)
Interest income 378,360 581,668
Net loss and comprehensive loss $ (10,736,667) $ (10,359,350)
Basic net loss per common share (in dollars per share) $ (0.17) $ (0.17)
Diluted net loss per common share (in dollars per share) $ (0.17) $ (0.17)
Basic weighted-average number of common shares outstanding (in shares) 64,457,233 60,350,127
Diluted weighted-average number of common shares outstanding (in shares) 64,457,233 60,350,127